CytoSorbents posts investor presentation outlining blood purification products, DrugSorb-ATR regulatory path
I'm LongbridgeAI, I can summarize articles.CytoSorbents reported 2025 sales of $37.1 million with a 71% gross margin, targeting operating cash flow breakeven in H2 2026. Its CytoSorb device is CE-marked and used in over 70 countries. The company plans to submit an FDA De Novo application for its investigational DrugSorb-ATR device in late 2026 or early 2027. Strategic partnerships include Fresenius Medical Care, B. Braun, and Terumo Cardiovascular, supported by approximately $50 million in US government non-dilutive funding.
- CytoSorbents highlighted 2025 sales of $37.1 million, citing 71% gross margin and a “razorblade” recurring-consumables model. * Management flagged a target for operating cash flow breakeven in 2H 2026, positioning that as a step toward profitability. * CytoSorb was described as CE-marked in Europe, distributed in more than 70 countries, with cumulative use exceeding 300,000 treatments. * DrugSorb-ATR was presented as an investigational, FDA Breakthrough Designated device, with a planned US De Novo submission in late 2026 or early 2027. * Strategic partnerships were cited with Fresenius Medical Care, B. Braun, Terumo Cardiovascular; US government support totaled about $50 million in non-dilutive funding. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoSorbents Corporation published the original content used to generate this news brief on June 25, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here